Fig. 8
Resveratrol reduces ROS by activating the SIRT3-FoxO3a pathway. (a) Representative IF image indicating MitoSOX in shNC-Caco-2 cells and shSIRT3-Caco-2 cells treated with resveratrol and/or RSL3 (n = 3). Scale bars: 200 μm. (b) Quantitation of the MFI of MitoSOX in shNC-Caco-2 cells and shSIRT3-Caco-2 cells treated with resveratrol and/or RSL3 (n = 3). (c) Representative Western blots of SIRT3, FoxO3a, catalase and SOD2 in shNC-Caco-2 cells treated with resveratrol and/or RSL3 (n = 3). (d) Quantification of Foxo3a mRNA in siNC-Caco-2 and siFoxO3a-Caco-2 cells (n = 3). (e) Representative Western blots of FoxO3a in siNC-Caco-2 and siFoxO3a-Caco-2 cells (n = 3). (f) Quantitation of FoxO3a in siNC-Caco-2 and siFoxO3a-Caco-2 cells (n = 3). (g) Quantitation of SIRT3, FoxO3a, catalase and SOD2 in shNC-Caco-2 cells treated with resveratrol and/or RSL3 (n = 3). (h) Representative Western blots of catalase and SOD2 in siNC-Caco-2 cells and siFoxO3a-Caco-2 cells treated with resveratrol and/or RSL3 (n = 3). (i) Quantitation of catalase and SOD2 in siNC-Caco-2 and siFoxO3a-Caco-2 cells treated with resveratrol and/or RSL3 (n = 3). The data are presented as the mean ± SD of three independent experiments in triplicates. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. One-way ANOVA (d, f), two-way ANOVA (b, g, i)